株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

オーファンドラッグ (希少疾病用医薬品) の世界市場

Orphan Drugs

発行 Global Industry Analysts, Inc. 商品コード 285000
出版日 ページ情報 英文 149 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.91円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
オーファンドラッグ (希少疾病用医薬品) の世界市場 Orphan Drugs
出版日: 2020年02月01日 ページ情報: 英文 149 Pages
概要

当レポートでは、世界のオーファンドラッグ市場について調査し、市場の概要と競合動向、製品概要、地域別の動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 業界概要
    • 序論
    • メーカーによるオーファンドラッグ導入増加
    • 1983年のオーファンドラッグ法が業界のキックスタート
    • 世界の主なオーファンドラッグ法規制
    • オーファンドラッグ市場は急速に成長
    • 米国、カナダ、EUにおける奇病対応組織
    • 米国、EU、日本におけるオーファンドラッグに対する取り組み
    • 市場の課題
    • オーファンドラッグ研究を実施する際の障壁
    • 競合
    • オーファンドラッグは医薬品パイプラインにおいて強固な状態を維持
    • パイプラインにある重要なオーファンドラッグ
  • 成長促進因子
    • 法規制インセンティブ
    • アンメットニーズの増大
    • 稀な癌の発症率上昇
    • 癌のためのオーファンドラッグ
    • 腎細胞癌の発症率上昇
    • 高齢化
    • 症状が出る前の検査
    • アジアの認知度向上
  • 市場動向
  • オーファンドラッグに対するFDAの認可
  • オーファンドラッグ指定
  • 法規制シナリオ
  • 製品概要
    • オーファンドラッグ:序論
    • オーファンドラッグの研究進捗
    • オーファンドラッグの定義 他
  • 製品認可/上市
  • 近年の業界活動
  • 主要企業
    • AbbVie, Inc.
    • Actelion Pharmaceuticals Ltd.
    • Alexion Pharmaceuticals, Inc.
    • Amgen, Inc.
    • AstraZeneca Plc.
    • Bayer AG
    • Biogen Inc.
    • BioMarin Pharmaceutical Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Celgene Corp.
    • CEL-SCI Corporation
    • Concordia International Corp.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Merck Serono International S.A.
    • Novartis AG
    • Pfizer, Inc.
    • Recordati S.p.A.
    • Orphan Europe
    • Shire Plc.
    • Sanofi SA
    • Genzyme Corp.
    • Vertex Pharmaceuticals
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • その他の諸国
目次
Product Code: MCP-7443

Orphan Drugs market worldwide is projected to grow by US$199 Billion, driven by a compounded growth of 13.1%. Biologics, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$203.1 Billion by the year 2025, Biologics will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 14.2% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$8 Billion to the region's size and clout in the next 5 to 6 years. Over US$9.5 Billion worth of projected demand in the region will come from Rest of Europe markets. In Japan, Biologics will reach a market size of US$15 Billion by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 13% over the next couple of years and add approximately US$35.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others,

  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • CEL-SCI Corporation
  • Concordia International Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Merck Serono International S.A.
  • Novartis AG
  • Pfizer Inc.
  • Recordati S.p.A.
  • Shire Plc.
  • Sanofi SA
  • Genzyme Corp.,Vertex Pharmaceuticals

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • A Prelude
  • Recent Market Activity
  • Increasing Adoption of Orphan Drugs by Manufacturers
  • The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
  • Major Orphan Drugs Legislations Worldwide
  • Orphan Drugs Market on a Rapid Growth Trajectory
  • Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU
  • Incentives for Orphan Drug Designation Products in the US, EU, and Japan
  • Market Challenges
  • Obstacles for Conducting Orphan Drug Research
  • Competition
  • Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
  • Important Orphan Drugs in Pipeline
  • Global Competitor Market Shares
  • Orphan Drugs Competitor Market Share Scenario Worldwide (in %): 2020 & 2029

2. FOCUS ON SELECT PLAYERS

  • AbbVie, Inc.
  • Actelion Pharmaceuticals Ltd.
  • Alexion Pharmaceuticals, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corp.
  • CEL-SCI Corporation
  • Concordia International Corp.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Merck Serono International S.A.
  • Merck Serono International S.A.
  • Novartis AG
  • Pfizer, Inc.
  • Recordati S.p.A.
  • Orphan Europe
  • Shire Plc.
  • Sanofi SA
  • Genzyme Corp.
  • Vertex Pharmaceuticals

3. MARKET TRENDS & DRIVERS

  • Regulatory Incentives - A Push in the Right Direction
  • Growing Unmet Medical Needs - Fulfilling the Gap
  • Rising Incidence of Rare Forms of Cancer - Opportunities Galore
  • Select Orphan Drugs for Cancer
  • Rise in Incidence of Renal Cell Carcinoma
  • Unmet Needs in AML
  • Aging Population Offers Growth Potential
  • Pre-Symptomatic Screening to Expand Market Base
  • Asia's Rising Awareness and Growing Population to Drive Sales
  • Drug Repurposing Provides Therapies for Rare Diseases
  • The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
  • Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics
  • Mergers and Acquisitions Drive Market Growth
  • Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
  • Growing Scrutiny over Skyrocketing Prices
  • Orphan Drugs with High Prices: 2016
  • Medical Advancements Foster Growth
  • Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs
  • Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
  • Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis
  • Increasing Patient Engagement - The PAG Trend
  • Gene Therapy and Bioprocessing Preferred over Chronic Therapies
  • Companies Developing Gene Therapies
  • International Collaboration - The Way Forward
  • CNS Therapeutics to Gain Focus in the Orphan Drugs Market
  • Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications
  • Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications
  • Treating Autism - The Next Big Thing?
  • Sequencing Technology - The New Research Tool for Orphan Drugs
  • Innovations in Biotechnology - A Boon for Orphan Drug Research
  • Aging Gene Linked to Myeloma
  • Antibody with Potential to Treat Multiple Myeloma
  • Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus
  • Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: Orphan Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
  • TABLE 2: Orphan Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
  • TABLE 3: Orphan Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Biologics (Drug Type) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 5: Biologics (Drug Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 6: Biologics (Drug Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Non-Biologics (Drug Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
  • TABLE 8: Non-Biologics (Drug Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
  • TABLE 9: Non-Biologics (Drug Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Oncology (Disease Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
  • TABLE 11: Oncology (Disease Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
  • TABLE 12: Oncology (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 13: Hematology (Disease Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
  • TABLE 14: Hematology (Disease Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 15: Hematology (Disease Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 16: Neurology (Disease Type) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 17: Neurology (Disease Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 18: Neurology (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 19: Cardiovascular (Disease Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
  • TABLE 20: Cardiovascular (Disease Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 21: Cardiovascular (Disease Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 22: Other Disease Types (Disease Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025
  • TABLE 23: Other Disease Types (Disease Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017
  • TABLE 24: Other Disease Types (Disease Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Orphan Drugs Market Share (in %) by Company: 2020 & 2025
    • Market Analysts
    • TABLE 25: United States Orphan Drugs Market Estimates and Projections in US$ Million by Drug Type: 2018 to 2025
    • TABLE 26: Orphan Drugs Market in the United States by Drug Type: A Historic Review in US$ Million for 2009-2017
    • TABLE 27: United States Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 28: United States Orphan Drugs Market Estimates and Projections in US$ Million by Disease Type: 2018 to 2025
    • TABLE 29: Orphan Drugs Market in the United States by Disease Type: A Historic Review in US$ Million for 2009-2017
    • TABLE 30: United States Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025
  • CANADA
    • TABLE 31: Canadian Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018 to 2025
    • TABLE 32: Canadian Orphan Drugs Historic Market Review by Drug Type in US$ Million: 2009-2017
    • TABLE 33: Orphan Drugs Market in Canada: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025
    • TABLE 34: Canadian Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018 to 2025
    • TABLE 35: Canadian Orphan Drugs Historic Market Review by Disease Type in US$ Million: 2009-2017
    • TABLE 36: Orphan Drugs Market in Canada: Percentage Share Breakdown of Sales by Disease Type for 2009, 2019, and 2025
  • JAPAN
    • TABLE 37: Japanese Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Type for the Period 2018-2025
    • TABLE 38: Orphan Drugs Market in Japan: Historic Sales Analysis in US$ Million by Drug Type for the Period 2009-2017
    • TABLE 39: Japanese Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 40: Japanese Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Disease Type for the Period 2018-2025
    • TABLE 41: Orphan Drugs Market in Japan: Historic Sales Analysis in US$ Million by Disease Type for the Period 2009-2017
    • TABLE 42: Japanese Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025
  • CHINA
    • TABLE 43: Chinese Orphan Drugs Market Growth Prospects in US$ Million by Drug Type for the Period 2018-2025
    • TABLE 44: Orphan Drugs Historic Market Analysis in China in US$ Million by Drug Type: 2009-2017
    • TABLE 45: Chinese Orphan Drugs Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 46: Chinese Orphan Drugs Market Growth Prospects in US$ Million by Disease Type for the Period 2018-2025
    • TABLE 47: Orphan Drugs Historic Market Analysis in China in US$ Million by Disease Type: 2009-2017
    • TABLE 48: Chinese Orphan Drugs Market by Disease Type: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
    • Market Facts & Figures
    • European Orphan Drugs Market: Competitor Market Share Scenario (in %) for 2020 & 2025
    • Market Analysts
    • TABLE 49: European Orphan Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025
    • TABLE 50: Orphan Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
    • TABLE 51: European Orphan Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 52: European Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018-2025
    • TABLE 53: Orphan Drugs Market in Europe in US$ Million by Drug Type: A Historic Review for the Period 2009-2017
    • TABLE 54: European Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 55: European Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018-2025
    • TABLE 56: Orphan Drugs Market in Europe in US$ Million by Disease Type: A Historic Review for the Period 2009-2017
    • TABLE 57: European Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025
  • FRANCE
    • TABLE 58: Orphan Drugs Market in France by Drug Type: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 59: French Orphan Drugs Historic Market Scenario in US$ Million by Drug Type: 2009-2017
    • TABLE 60: French Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 61: Orphan Drugs Market in France by Disease Type: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 62: French Orphan Drugs Historic Market Scenario in US$ Million by Disease Type: 2009-2017
    • TABLE 63: French Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025
  • GERMANY
    • TABLE 64: Orphan Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Type for the Period 2018-2025
    • TABLE 65: German Orphan Drugs Historic Market Analysis in US$ Million by Drug Type: 2009-2017
    • TABLE 66: German Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 67: Orphan Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Disease Type for the Period 2018-2025
    • TABLE 68: German Orphan Drugs Historic Market Analysis in US$ Million by Disease Type: 2009-2017
    • TABLE 69: German Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025
  • ITALY
    • TABLE 70: Italian Orphan Drugs Market Growth Prospects in US$ Million by Drug Type for the Period 2018-2025
    • TABLE 71: Orphan Drugs Historic Market Analysis in Italy in US$ Million by Drug Type: 2009-2017
    • TABLE 72: Italian Orphan Drugs Market by Drug Type: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 73: Italian Orphan Drugs Market Growth Prospects in US$ Million by Disease Type for the Period 2018-2025
    • TABLE 74: Orphan Drugs Historic Market Analysis in Italy in US$ Million by Disease Type: 2009-2017
    • TABLE 75: Italian Orphan Drugs Market by Disease Type: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
    • TABLE 76: United Kingdom Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Type for the Period 2018-2025
    • TABLE 77: Orphan Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Type for the Period 2009-2017
    • TABLE 78: United Kingdom Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 79: United Kingdom Market for Orphan Drugs: Annual Sales Estimates and Projections in US$ Million by Disease Type for the Period 2018-2025
    • TABLE 80: Orphan Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Disease Type for the Period 2009-2017
    • TABLE 81: United Kingdom Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018-2025
    • TABLE 83: Orphan Drugs Market in Rest of Europe in US$ Million by Drug Type: A Historic Review for the Period 2009-2017
    • TABLE 84: Rest of Europe Orphan Drugs Market Share Breakdown by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 85: Rest of Europe Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018-2025
    • TABLE 86: Orphan Drugs Market in Rest of Europe in US$ Million by Disease Type: A Historic Review for the Period 2009-2017
    • TABLE 87: Rest of Europe Orphan Drugs Market Share Breakdown by Disease Type: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
    • TABLE 88: Orphan Drugs Market in Asia-Pacific by Drug Type: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 89: Asia-Pacific Orphan Drugs Historic Market Scenario in US$ Million by Drug Type: 2009-2017
    • TABLE 90: Asia-Pacific Orphan Drugs Market Share Analysis by Drug Type: 2009 VS 2019 VS 2025
    • TABLE 91: Orphan Drugs Market in Asia-Pacific by Disease Type: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 92: Asia-Pacific Orphan Drugs Historic Market Scenario in US$ Million by Disease Type: 2009-2017
    • TABLE 93: Asia-Pacific Orphan Drugs Market Share Analysis by Disease Type: 2009 VS 2019 VS 2025
  • REST OF WORLD
    • TABLE 94: Rest of World Orphan Drugs Market Estimates and Forecasts in US$ Million by Drug Type: 2018 to 2025
    • TABLE 95: Rest of World Orphan Drugs Historic Market Review by Drug Type in US$ Million: 2009-2017
    • TABLE 96: Orphan Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Drug Type for 2009, 2019, and 2025
    • TABLE 97: Rest of World Orphan Drugs Market Estimates and Forecasts in US$ Million by Disease Type: 2018 to 2025
    • TABLE 98: Rest of World Orphan Drugs Historic Market Review by Disease Type in US$ Million: 2009-2017
    • TABLE 99: Orphan Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Disease Type for 2009, 2019, and 2025

IV. COMPETITION

  • Total Companies Profiled: 140
  • ORPHAN DRUGS MCP-7443
  • CONTENTS
Back to Top